Industry News
Biotechnology Industry News

With a few chemical tweaks and…
With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked the code to turn DNA into a brand-new class of therapeutics.
China’s biotech rise has been a…
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring.
Learn how early intervention can…
Learn how early intervention can help drug developers convert suboptimal formulations into scalable, clinically viable solutions.
After its bet on a rare eye…
After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning the asset to sender as MeiraGTx buys back back full rights to botaretigene sparoparvovec
Storm Therapeutics has closed a…
Storm Therapeutics has closed a $56 million series C financing and launched a Phase 2 trial of its lead asset for sarcoma patients.
Aligos Therapeutics has secured a…
Aligos Therapeutics has secured a $25 million upfront fee from hepatology biopharma Amoytop in exchange for the China rights to its phase 2-stage chronic hepatitis B virus (HBV) treatment.
A slow start to 2026 has put…
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing the already limited funding opportunities available for startups.
In a complex therapeutic…
In a complex therapeutic landscape, WuXi AppTec is simplifying the path from discovery to patient. Find out how.
The Spanish government has…
The Spanish government has announced a goal to raise a $200 million venture capital fund to launch the Spain-Boston biotechnology initiative to expand international collaboration.
The steady stream of IPOs…
The steady stream of IPOs evaporated almost as quickly as it had appeared. So what happened?
Terremoto Biosciences has spelt…
Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to continue its efforts to broaden the covalent drug alphabet.
The FDA’s newly launched…
The FDA’s newly launched plausible mechanism framework may have been forged in the image of individualized therapies, but its principles are not confined to the bespoke, Teresa Buracchio, M.D., head of the FDA’s Office of
The former leaders of SpringWorks…
The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 million series A.
After initiating a wind-down more…
After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that will take oncology-focused Obsidian public.
Astellas is preparing to close its…
Astellas is preparing to close its Seattle site for its stem cell therapy unit, with around 55 employees set to be affected.
Takeda has pulled back from a…
Takeda has pulled back from a research collaboration with a fellow Japanese life sciences company, ending work to discover new small molecules that target mRNA.
Kazia Therapeutics is paying $1.4…
Kazia Therapeutics is paying $1.4 million upfront to secure a platform for generating epigenetic drugs from an Australian research institute.
Eli Lilly has turned its attention…
Eli Lilly has turned its attention down south with a $300 million biobuck acquisition of Houston-based CrossBridge Bio, aiming to advance its dual-payload antibody-drug conjugate (ADCs) pipeline.
An FDA review of records found…
An FDA review of records found that results have not been reported for 30% of registered clinical studies. To remedy this shortfall, the U.S. regulator has sent reminders to 2,200 drug companies, medical device manufacturers
Discover how biomarker strategies…
Discover how biomarker strategies are transforming oncology trials and accelerating precision medicine breakthroughs.

